Inhibitors of tyk2
US-2024425484-A1 · Dec 26, 2024 · US
USRE48928E · US · E1
| Field | Value |
|---|---|
| Publication number | US-RE48928-E |
| Application number | US-201416858380-A |
| Country | US |
| Kind code | E1 |
| Filing date | Mar 14, 2014 |
| Priority date | Mar 15, 2013 |
| Publication date | Feb 15, 2022 |
| Grant date | Feb 15, 2022 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Embodiments of methods and compounds for isolating and detecting lysophosphatidic acids (LPAs) are disclosed. Kits for performing the methods also are disclosed. LPAs are isolated from biological samples by liquid-liquid extraction followed by solid phase extraction. LPA species may be separated by HPLC, and the separated species may be identified and quantified. Also disclosed are embodiments of compounds capable of universally detecting a plurality of LPA species with substantially equivalent sensitivity. Embodiments of the disclosed compounds are useful for determination of total LPA concentration in a sample comprising a plurality of LPA species without separation of individual LPA species.
Opening claim text (preview).
We claim: 1. A compound according to (a) general formula I wherein: R 1 -R 6 independently are hydrogen, hydroxyl, thiol, C 1 -C 10 alkyl, carboxyalkyl, amino, C 1 -C 10 alkoxy, or halogen, R 7 -R 10 independently are hydrogen, alkyl, acyl, carboxyl, nitro, amino, alkylamino, or —SO 3 H, R 11 is N—C(═R 13 )—NH 2 , N—C(NH 2 )═N—C(═R 13 )—NH 2 , or N—NH—C(NH 2 )═N—C(═R 13 )—NH 2 , where R 13 is O, S, or NH, or R 11 is N—NH—C(═R 13 )—NH 2 , where R 13 is O or NH, each R 12 independently is hydrogen or lower alkyl, or each of R 1 , R 2 , R 5 , and R 6 may together with an adjacent R 12 and N atom form a 6-membered heterocyclic ring, and X is O, S, CH 2 , NH, or SiR 14 where R 14 is H or C 1 -C 10 alkyl; or (b) general formula II wherein: R 1 -R 5 , R 15 , R 17 , and R 18 independently are hydrogen, hydroxyl, thiol, C 1 -C 10 alkyl, carboxyalkyl, amino, C 1 -C 10 alkoxy, or halogen, R 16 is —N(R 12 ) 2 , R 7 -R 10 independently are hydrogen, alkyl, acyl, carboxyl, nitro, amino, alkylamino, or —SO 3 H, R 11 is N—C(═R 13 )—NH 2 , N—NH—C(═R 13 )—NH 2 , N—C(NH 2 )═N—C(═R 13 )—NH 2 , or N—NH—C(NH 2 )═N—C(═R 13 )—NH 2 , where R 13 is O, S, or NH, each R 12 independently is hydrogen or C 1 -C 10 alkyl, or each of R 1 , R 2 , R 15 , and R 17 may together with an adjacent R 12 and N atom form a 6-membered heterocyclic ring, and X is O, S, CH 2 , NH, or SiR 14 where R 14 is H or C 1 -C 10 alkyl; or (c) general formula III wherein: R 2 -R 5 , R 15 , R 17 , and R 19 -R 21 independently are hydrogen, hydroxyl, thiol, C 1 -C 10 alkyl, carboxyalkyl, amino, C 1 -C 10 alkoxy, or halogen, one of R 16 and R 18 is hydrogen, hydroxyl, thiol, lower alkyl, carboxyalkyl, amino, C 1 -C 10 alkoxy, or halogen, and the other of R 16 and R 18 is —N(R 12 ) 2 , R 7 -R 10 independently are hydrogen, alkyl, acyl, carboxyl, nitro, amino, alkylamino, or —SO 3 H, R 11 is N—C(═R 13 )—NH 2 , N—NH—C(═R 13 )—NH 2 , N—C(NH 2 )═N—C(═R 13 )—NH 2 , or N—NH—C(NH 2 )═N—C(═R 13 )—NH 2 , where R 13 is O, S, or NH, each R 12 independently is hydrogen or C 1 -C 10 alkyl, or if R 16 is —N(R 12 ) 2 , each of R 15 , R 17 , R 20 , and R 21 may together with an adjacent R 12 and N form a 6-membered heterocyclic ring, and X is O, S, CH 2 , NH, or SiR 14 where R 14 is H or C 1 -C 10 alkyl; or (d) general formula IV wherein: R 1 -R 4 , R 6 , and R 22 -R 24 independently are hydrogen, hydroxyl, thiol, C 1 -C 10 alkyl, carboxyalkyl, amino, C 1 -C 10 alkoxy, or halogen, R 7 -R 10 independently are hydrogen, alkyl, acyl, carboxyl, nitro, amino, alkylamino, or —SO 3 H, R 11 is N—C(═R 13 )—NH 2 , N—NH—C(═R 13 )—NH 2 , N—C(NH 2 )═N—C(═R 13 )—NH 2 , or N—NH—C(NH 2 )═N—C(═R 13 )—NH 2 , where R 13 is O, S, or NH, each R 12 independently is hydrogen or C 1 -C 10 alkyl, or each of R 1 , R 2 , R 23 , and R 24 may together with an adjacent R 12 and N form a 6-membered heterocyclic ring, and X is O, S, CH 2 , NH, or SiR 14 where R 14 is H or C 1 -C 10 alkyl. 2. The compound of claim 1 , wherein X is O. 3. The compound of claim 1 according to: general formula I, wherein R 1 -R 10 are H; general formula II, wherein R 1 -R 5 ; R 7 -R 10 , R 15 , R 17 , and R 18 are hydrogen; general formula III, wherein R 2 -R 5 ; R 7 -R 10 , R 15 , R 17 , and R 19 -R 21 are hydrogen, one of R 16 and R 18 is hydrogen, and the other of R 16 and R 18 is —N(R 12 ) 2 ; or general formula IV, wherein R 1 -R 4 , R 6-10 , and R 22 -R 24 are hydrogen. 4. The compound of claim 1 , wherein the compound is 5. A method for quantifying lysophosphatidic acid species, comprising: combining a sample that may include one or more lysophosphatidic acid species with a compound according to claim 1 in a solvent comprising dimethylsulfoxide in methanol to form a solution; exposing the solution to a light source; measuring fluorescence intensity of the solution; and determining, based on the fluorescence intensity, a total concentration of lysophosphatidic acid species in the sample. 6. The method of claim 5 , further comprising obtaining the sample by extracting lysophosphatidic acid species from a sample comprising plasma or serum, wherein the sample comprising plasma or serum is obtained from a subject suspected of being at risk of a condition associated with an aberrant LPA level, the method further comprising determining a risk level for the condition, wherein the risk level is based at least in part on the total concentration of lysophosphatidic acid species. 7. The method of claim 5 , wherein the compound is and fluorescence intensity is measured at 570 nm. 8. The method of claim 6 , wherein the condition is cancer, cardiovascular disease, platelet aggregation, ischemia perfusion injury, neuropathic pain, a neuropsychiatric disorder, a reproductive disorder, or fibrosis. 9. A kit for detecting and quantifying lysophosphatidic acid, comprising at least one compound according to claim 1 . 10. The kit of claim 9 , wherein the compound is 11. The method of claim 6 , wherein the condition is ovarian cancer. 12. The method of claim 6 , wherein extracting lysophosphatidic acid species from the sample comprising plasma or serum further comprises: combining the sample comprising plasma or serum with a an organic solvent comprising a C 1 -C 10 alkyl alcohol and chloroform to form a mixture; separating organic and aqueous layers of the mixture; extracting the aqueous layer with a buffer at neutral pH to form an extracted aqueous phase; mixing the extracted aqueous phase with chloroform; separating chloroform from the extracted aqueous phase to form a washed aqueous phase; adding phosphoric acid to the washed aqueous phase to form an acidified aqueous phase; loading the acidified aqueous phase onto a solid-phase extraction (SPE) cartridge including a stationary phase comprising silica derivatized with hydrocarbon chains; flowing water and subsequently chloroform through the SPE cartridge; drying the SPE cartridge; and flowing a C 1 -C 10 alkyl alcohol through the SPE cartridge, thereby eluting lysophosphatidic acid species in the C 1 -C 10 alkyl alcohol from the SPE cartridge. 13. The compound of claim 1 , wherein R 13 is NH. 14. The method of claim 12, wherein extracting lysophosphatidic acid species from the sample comprising plasma or serum further comprises: a chromatographic separation to measure levels of total LPA and individual LPA subspecies. 15. The method of claim 14, wherein the chromatographic separation is performed using a reversed-phase high-performance liquid chromatography column. 16. The method of claim 5, wherein the solvent comprises di
with only one oxygen atom as ring hetero atom in the oxygen-containing ring · CPC title
in which the condensed system contains four or more hetero rings · CPC title
Phthaleins containing amino groups {; Phthalanes; Fluoranes; Phthalides; Rhodamine dyes; Phthaleins having heterocyclic aryl rings; Lactone or lactame forms of triarylmethane dyes} · CPC title
involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)} · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.